Promising New PD Fluid
In a Phase 2 study, PD-protec® from Zytoprotec in Vienna, Austria, reduced the risk of peritonitis and of membrane failure. The new fluid was well-tolerated, with no adverse events. Once on the market, this fluid could improve PD outcomes and allow more people to stay longer on the therapy.
Read the full article » | Posted 07-14-2017
Related Articles
- Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026
- FDA granted 510(k) approval to Outset for Next generation Tablo with Cybersecurity Posted 02-17-2026
- Drs. Monica Farcus and Jeffrey Perl Win the Mitchell Award for Health System Innovation Posted 01-16-2026
- Nephrodite Wins FDA Breakthrough Device Designation for “Holly” Posted 01-16-2026